middle.news
Can Argenica’s ARG-007 Breakthrough Shift Stroke Treatment Landscape?
2:55am on Saturday 30th of August, 2025 AEST
•
Health Care
Read Story
Can Argenica’s ARG-007 Breakthrough Shift Stroke Treatment Landscape?
2:55am on Saturday 30th of August, 2025 AEST
Key Points
Revenue up 34% to $3.73 million, boosted by R&D tax incentives and grants
Loss after tax increased 31% to $7.17 million, reflecting higher R&D expenses
Phase 2 clinical trial of ARG-007 for acute ischemic stroke completed dosing
Received $1.5 million in non-dilutive government funding for neurological research
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE